An Unusual Complication of Cabergoline Treatment of Macroprolactinomas

Amal Moumena, e, Sanae Chakdoufa, Hamza El Jadi, Ouijdane Zammanic, Cherif Abad El Asrid, Ghizlaine Belmejdoub

Abstract

Dopamine agonist (DA) treatment is the first choice treatment of prolactinomas. Optic chiasm prolapse with secondary visual deterioration is an unusual and rare complication of DA treatment. A 40-year-old man with giant prolactinoma was successfully treated by cabergoline. After 14 months, he presented with a visual impairment with no ophthalmologic anomalies that could explain this worsening. The pituitary magnetic resonance imaging (MRI) revealed an important shrinkage of prolactinoma with a prolapse and a central atrophy of optic chiasm secondary to the adenoma shrinkage. This case highlights the need of regular assessment of visual field all along cabergoline treatment of macroprolactinomas despite initial improvement or even normalization of visual field, to promptly identify an optic chiasm prolapse and avoid the optic chiasm atrophy.

Keywords: Cabergoline; Optic chiasm prolapse; Macroprolactinoma

Introduction

Prolactinomas represent 30-40% of all pituitary tumors [1]. Dopamine agonist (DA) is the first-line treatment of prolactinomas even giant macroprolactinomas with visual deterioration. Cabergoline has been reported as the most effective in normalizing prolactin levels and inducing tumor shrinkage [2]. Common side effects of DA treatment include headaches, nausea and vomiting, fatigue, orthostatic hypotension, peripheral vascular changes and depression [3]. Pituitary apoplexy and cerebrospinal fluid rhinorrhea are considered rare side effects of DA treatment [4, 5]. We report an unusual case of secondary visual field deterioration during cabergoline treatment of a giant prolactinoma, despite tumor shrinkage, related to optic chiasm prolapse.

Case Report

A 40-year-old man with no medical history presented with chronic headaches, progressive visual field loss, poor libido and erectile dysfunction. The patient also reported a long history of tiredness, cold intolerance, constipation and gain weight without lifestyle changes. General examination revealed a bradycardia with a pulse rate at 54/min, blood pressure at 100/60 mm Hg and a body mass index of 32 kg/m². He had a pale face with thinning of the outer third of the eyebrow and bilateral gynecomastia. Ophthalmologic exam showed a visual acuity of 4/10 at the right eye and 1/10 at the left eye. Visual field perimetry revealed a right superior temporal quadrantanopsia and left temporal hemianopsia (Fig. 1a). Pituitary magnetic resonance imaging (MRI) revealed a heterogeneous giant pituitary adenoma of 50 × 47 × 27 mm in diameter, moderately enhanced following gadolinium injection, bulging in the sphenoidal sinus and with bilateral contact with cavernous sinuses. The adenoma was extending into the suprasellar region, thus compressing the optic chiasm.

Formal endocrine testing revealed panhypopituitarism and a markedly elevated prolactin level of > 10,000 ng/mL (normal range < 25 ng/mL), confirming the diagnosis of macroprolactinomas. Insulin-like growth factor-1 (IGF-1) was normal.

The patient was started on cabergoline treatment 2 mg/week in addition to replacement therapy initially with hydrocortisone (20 mg daily) and then with L-thyroxine (50 µg daily). After 1 month of cabergoline, patient reported a subjective visual improvement but prolactin level was still elevated at > 470 ng/mL and visual field perimetry was worsening. The cabergoline doses were increased to 3 mg/week with subsequent normalization of prolactin level and visual acuity and visual field improvement (Fig. 1b). Three months later, pituitary MRI showed a decrease of the adenoma size to 28 × 33 × 29 mm without contact with the optic chiasm (Fig. 2).

After 14 months of cabergoline treatment, the ophthal-
mologist reported a secondary visual field deterioration (Fig. 1c) with no ophthalmologic anomalies that could explain this worsening. An urgent pituitary MRI was conducted to exclude pituitary hemorrhage or infarction. It revealed an important shrinkage of adenoma’s height from 28 to 6 mm with a prolapse and central atrophy of optic chiasm secondary to tumor shrinkage (Fig. 3).

Cabergoline treatment was withdrawn for 2 weeks, and then restarted at a lower dose (4 mg/week) with stabilization of visual fields and visual acuity.

Discussion

Secondary deterioration in visual fields after successful medical treatment for a macroprolactinoma may be caused by pituitary apoplexy or tumor regrowth. Optic chiasm prolapse secondary to dramatic shrinkage of macroprolactinoma is a rare and an under-recognized complication of DA treatment [6]. The optic chiasm herniation has been described in patients with macroprolactinoma, treated with bromocriptine [6-8], pergolide [9], or cabergoline [10]. The mechanism of the secondary visual impairment due to optic chiasm prolapse after DA treatment is unclear. The adherence of the adenoma to the suprasellar visual system before DA treatment could predispose to the herniation upon reduction of the adenoma size by treatment and subsequent development of empty sella [6, 7, 11]. The chiasm or optic nerves were dragged down into the sella by scarred tissue and adherence may directly compromise the chiasm’s vascular supply [6, 7]. However, prolapse of the optic chiasm without visual field defect is very common and no correlation has been found between the degree of chiasmal herniation and the severity of the visual loss [7]. Direct toxicity of dopaminergic agonist agents, vasospasm-induced ischemia, or reversible perivascular fibrosis has been suggested [10]. This is consistent with the improvement in visual fields observed after withdrawal or reduction in therapeutic dosage [10].

In our case, the tumor was initially adherent to the suprasellar visual system and the increase of cabergoline dose may have induced intratumoral fibrosis, tumor shrinkage and alteration of vascular supply, thus causing optic chiasm prolapse.

Figure 1. (a) Initial visual fields showing right superior temporal quadrantanopsia and left temporal hemianopsia. (b) After 2 months of cabergoline treatment, visual fields showing improvement in the temporal fields. (c) After 14 months of cabergoline treatment, visual field showing a secondary deterioration of temporal field.
and atrophy.

The treatment of patients with macroprolactinoma complicated by optic chiasma prolapse consists of DA dosage reduction, withdrawal, or surgical treatment.

DA withdrawal and re-initiation at a lower dose is hypothesized to relieve the tension on the optic chiasm with only limited tumor regrowth [6, 10]. This therapeutic strategy was reported by many authors. A visual improvement to normal was reported in five cases within 2 weeks to 12 months [6, 7, 9, 10]. A significant improvement in two cases [10] and marginal improvement in one case were reported [12].

The other therapeutic alternative is surgery by performing a chiasmapexy. The goals of chiasmapexy are either lysis of the adhesions between the optic chiasm and dura or elevation of the dura itself [13]. The former requires a craniotomy and intradural exposure, and the latter can be done through an extradural minimally invasive endonasal endoscopic approach [13]. The extradural trans-sphenoidal approach reduces the risk of cerebrospinal fluid leakage as well as the risk of ischemia to the chiasm [13]. This approach was undertaken successfully in three patients with significant improvement of visual function [13-15]. However, the experience of the neurosurgeon is an important factor of success of this approach.

For our patient, we chose a medical approach because of the atrophy of optic chiasm to avoid a risk of worsening the optic chiasm impairment.

Learning points

DA remains the first choice therapy of macroprolactinomas. However, the clinician should be very careful when there is adherence between adenoma and the suprasellar visual system before treatment. In these cases, DA treatment should be initiated very gradually with regular assessment of visual field perimetry all along the treatment to avoid a dramatic shrinkage of the tumor and optic chiasm prolapse.

Acknowledgments

None to declare.
Financial Disclosure

None to declare.

Conflict of Interest

None to declare.

Informed Consent

Written informed consent has been obtained from the patient.

Author Contributions

AM collected the case data and prepared the initial manuscript. OZ was involved in expert review of imaging. AM, HJ and SC proofread and revised the manuscript. CAA and GB reviewed the manuscript. All the authors have read and agreed to the final manuscript.

Data Availability

The authors declare that data supporting the findings of this study are available within the article.

References